• Target：
• PPAR-γ

• Fields：
• >>PPAR signaling pathway;>>AMPK signaling pathway;>>Longevity regulating pathway;>>Osteoclast differentiation;>>Thermogenesis;>>Non-alcoholic fatty liver disease;>>Huntington disease;>>Pathways in cancer;>>Transcriptional misregulation in cancer;>>Thyroid cancer;>>Lipid and atherosclerosis

• Gene Name：
• PPARG

• Protein Name：
• Peroxisome proliferator-activated receptor gamma

• Human Gene Id：
• 5468

• Human Swiss Prot No：
• P37231

• Mouse Gene Id：
• 19016

• Mouse Swiss Prot No：
• P37238

• Rat Gene Id：
• 25664

• Rat Swiss Prot No：
• O88275

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human PPAR-gamma around the phosphorylation site of Ser112. AA range:78-127

• Specificity：
• Phospho-PPAR-γ (S112) Polyclonal Antibody detects endogenous levels of PPAR-γ protein only when phosphorylated at S112.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. ELISA: 1:10000. Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• PPARG;NR1C3;Peroxisome proliferator-activated receptor gamma;PPAR-gamma;Nuclear receptor subfamily 1 group C member 3

• Observed Band(KD)：
• 60kD

• Background：
• peroxisome proliferator activated receptor gamma(PPARG) Homo sapiens This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008],

• Function：
• alternative products:Additional isoforms seem to exist,disease:Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.,disease:Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension.,disease:Defects in PPARG may be associated with colon cancer.,disease:Defects in PPARG may be associated with susceptibility to obesity [MIM:601665].,disease:Variation in PPARG is associated with carotid intimal medial thickness 1 (CIMT1) [MIM:609338]. CIMT is a measure of atherosclerosis that is independently associated with traditional atherosclerotic cardiovascular disease

• Subcellular Location：
• Nucleus. Cytoplasm. Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation.

• Expression：
• Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs